Tailoring targeted therapy to DNA repair-defective High-Grade Serous Ovarian Cancer

针对 DNA 修复缺陷的高级别浆液性卵巢癌定制靶向治疗

• 批准号: nhmrc : 1062702
• 负责人: A/Pr Clare Scott
• 金额: $ 53.49万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/tailoring-targeted-therapy-ovarian-cancer/455013
• 关键词: Tailoring; targeted; therapy; DNA; repair

Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and should be susceptible to new PARP inhibitor therapy, yet not all those respond. By developing a new model of studying human ovarian cancers in mice, we can discover markers to predict which ovarian cancers will respond best to these exciting new treatments.

卵巢癌是女性癌症死亡的主要原因，因为目前的治疗方法不足。一半的侵袭性卵巢癌有DNA修复异常，应该对新的PARP抑制剂治疗敏感，但并非所有这些都有反应。通过开发一种在小鼠中研究人类卵巢癌的新模型，我们可以发现预测哪些卵巢癌对这些令人兴奋的新疗法反应最好的标志物。